Special considerations with insulin therapy in older adults with diabetes mellitus

Drugs and Aging

Volumn 28, Issue 6, 2011, Pages 429-438

  Mooradian, Arshag D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Elderly; Insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AFREZZA; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; HUMULIN R U 500; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD GLUCOSE MONITORING; CARBOHYDRATE ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT ATTITUDE; POSTPRANDIAL STATE; PRIORITY JOURNAL; WEIGHT REDUCTION;

AGED; AMINO ACID SEQUENCE; BLOOD GLUCOSE; DIABETES MELLITUS; DRUG COMPOUNDING; FASTING; HUMANS; HYPERGLYCEMIA; INSULIN; MOLECULAR SEQUENCE DATA;

EID: 79958281608     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11590570-000000000-00000     Document Type: Article

References (61)

1. Paolisso G. Pathophysiology of diabetes in elderly people. Acta Biomed 2010; 81 Suppl. 1: 47-53
2. Mooradian AD. Mechanisms of age-related endocrine alterations: part II. Drugs Aging 1993; 3: 131-46
3. Saudek CD, Hill Golden S. Feasibility and outcomes of insulin therapy in elderly patients with diabetes mellitus. Drugs Aging 1999; 14: 375-85 (Pubitemid 29213777)
4. Mooradian AD, Bernbaum M, Albert SG. A narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006; 145: 125-34 (Pubitemid 46780586)
5. Cayea D, Boyd C, Durso SC. Individualizing therapy for older adults with diabetes mellitus. Drugs Aging 2007; 24: 851-63 (Pubitemid 47553793)
6. Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci 2004; 59: 148-53 (Pubitemid 38269147)
7. Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc 2003; 51: 745-53 (Pubitemid 36693422)
8. Blaum CS, Xue QL, Tian J, et al. Is hyperglycemia associated with frailty status in older women? J Am Geriatr Soc 2009; 57:840-7
9. Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci 2005; 60: 1206-11 (Pubitemid 41384494)
10. Volpato S, Leveille SG, Blaum C, et al. Risk factors for falls in older disabled women with diabetes: the women's health and aging study. J Gerontol A Biol Sci Med Sci 2005; 60: 1539-45 (Pubitemid 43146459)
11. Schwartz AV, Vittinghoff E, Sellmeyer DE, et al., Health, Aging, and Body Composition Study: diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31: 391-6
12. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-6 (Pubitemid 38637681)
13. Feil D, Weinreb J, Sultzer D. Psychiatric disorders and psychotropic medication use in elderly persons with diabetes. Ann Long Term Care 2006; 14: 39-47 (Pubitemid 44199286)
14. Brown JS, Vittinghoff E, Lin F, et al. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. Diabetes Care 2006; 29: 1307-12 (Pubitemid 44125927)
15. Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs 1996; 6: 931-41 (Pubitemid 26164163)
16. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000; 60: 95-113 (Pubitemid 30598820)
17. Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother 2003; 57: 231-9 (Pubitemid 36897689)
18. Chehade J, Mooradian AD. Drug therapy: current and emerging agents for hyperglycemia. In: Sinclair AJ, editor. Diabetes in old age. 3rd ed. Chichester: John Wiley & Sons, 2009: 245-64
19. Abbatecola AM, Paolisso G, Corsonello A, et al. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging 2009; 26 Suppl. 1: 53-62
20. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010; 30: 609-24
21. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705 (Pubitemid 46048557)
22. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008; 25: 913-25
23. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2009; 2: 203-14
24. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes. Drugs 2005; 65: 325-40 (Pubitemid 40223366)
25. Howey DC, Bowsher RR, Brunelle RL, et al. (Lys(B28), Pro(B29))-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402 (Pubitemid 24064246)
26. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62: 1945-81
27. Barlocco D. Insulin glulisine Aventis Pharma. Curr Opin Investigat Drugs 2003; 4:1240-4 (Pubitemid 37420112)
28. Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther 2003; 5: 57-66 (Pubitemid 36506091)
29. Rami B, Schober E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Eur J Pediatr 1997; 156: 838-40 (Pubitemid 27463125)
30. Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabetic Med. 1999; 16:332-8
31. Kurtzhals P, Haveland S, Jonassen I, et al. Albumin binding and time action of acylated insulins in various species. J Pharma Sci 1996; 85: 304-8 (Pubitemid 26082476)
32. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-12 (Pubitemid 40616620)
33. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63:1743-78 (Pubitemid 36999964)
34. Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin 2004; 20: 31-7 (Pubitemid 38063452)
35. Hamann A, Matthaei S, Rosak C, et al., HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.Diabetes Care 2003; 26: 1738-44 (Pubitemid 36929113)
36. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-6 (Pubitemid 30616801)
37. Riddle M, Rosenstock J, Gerich J. The treat-to-target trial. Diabetes Care 2003; 26: 3080-6
38. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007; 55: 182-8 (Pubitemid 46184392)
39. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-3 (Pubitemid 28487075)
40. Rosenstock J, Cefalu WT, Hollander PA, et al. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. Diabetes Technol Ther 2009; 11: 697-705
41. Rave K, Potocka E, Boss AH, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009; 11: 715-20
42. Pozzilli P, Raskin P, Parkin CG. Review of clinical trials: update on oral insulin spray formulation. Diabetes Obes Metab 2010; 12: 91-6
43. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010; 33: 1997-2003
44. Banks WA, Morley JE, Lynch JL, et al. Insulin detemir is not transported across the blood-brain barrier. Peptides 2010; 31: 2284-8
45. Mooradian AD, Chehade JM. Diabetes mellitus in older adults. Am J Ther. Epub 2011 Jan 18
46. Jamali R, Bachrach-Lindström M, Mohseni S. Continuous glucose monitoring system signals the occurrence of marked postprandial hyperglycemia in the elderly. Diabetes Technol Ther 2005; 7: 509-15 (Pubitemid 40847813)
47. Monnier L, Colette C, Boegner C, et al. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 2007; 33: 247-52 (Pubitemid 47418699)
48. Horani MH, Mooradian AD. Management of obesity in the elderly: special considerations. Treat Endocrinol 2002; 1: 387-98 (Pubitemid 37047450)
49. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28: 1568-73 (Pubitemid 40923066)
50. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-9 (Pubitemid 40170922)
51. Raskin P, Allen E, Hollander P, et al. INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005; 28:260-5 (Pubitemid 40170923)
52. Malone JK, Kerr LF, Campaigne BN, et al. Lispro Mixture- Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-44 (Pubitemid 40353613)
53. Clar C, Barnard K, Cummins E, et al., Aberdeen Health Technology Assessment Group. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14: 1-140
54. Thurman JE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States. Endocr Pract 2007; 13: 672-8
55. Bott U, Ebrahim S, Hirschberger S, et al. Effect of the rapidacting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetic Med 2003; 20: 626-34 (Pubitemid 36966556)
56. Dunn CJ, Plosker GL. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus. Pharmacoeconomics 2002; 20: 989-1025 (Pubitemid 35398697)
57. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Systematic Rev 2004; (2): CD003287
58. Durso SC. Using clinical guidelines for older adult patients with diabetes mellitus and complex health status. JAMA 2006; 295: 1935-40
59. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care 2010; 33 Suppl. 1: S62-9
60. Huang ES, Gorawara-Bhat R, Chin MH. Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 2005; 53: 306-11 (Pubitemid 41632559)
61. Maddigan SL, Feeny DH, Majumdar SR, et al. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006; 96: 1649-55 (Pubitemid 44300930)